Want to see SE:FLUI full AI Analyst Report?

Fluicell AB (FLUI) Price & Analysis

0 Followers

FLUI Stock Chart & Stats

kr10.00

>-kr0.01(-1.38%)

At close: Mar 06 4:00 PM EST

kr10.00

>-kr0.01(-1.38%)

Day’s Range― - ―

52-Week Rangekr7.65 - kr67.20

Previous CloseN/A

Volume175.18K

Average Volume (3M)3.01K

Market Cap

kr38.33M

Enterprise Valuekr43.46M

Total Cash (Recent Filing)kr30.00K

Total Debt (Recent Filing)kr2.00M

Price to Earnings (P/E)13.7

Beta1.07

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.04

Shares Outstanding1,373,703

10 Day Avg. Volume1,682

30 Day Avg. Volume3,011

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.26

Price to Sales (P/S)2.29

P/FCF Ratio-1.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr68.60M

Bulls Say, Bears Say

Bulls Say

Revenue And Profit InflectionTTM revenue growth of 67.4% alongside positive EBIT and net income shows a material operating inflection. If sustained, stronger sales can improve scale economics and provide a more durable base for product development and customer adoption.

High Gross MarginA gross margin near 91.6% indicates substantial value capture in the current product mix and leaves room to support operating investment as revenue expands. This provides a potentially strong economic foundation, although future periods must confirm its repeatability.

Modest Leverage And Equity BaseLow debt relative to equity and a substantial equity share of assets provide financial flexibility compared with a highly leveraged structure. This balance-sheet position can help Fluicell absorb operating variability and pursue its business plans without excessive debt pressure.

Bears Say

Negative Cash GenerationThe company remains unable to convert recent accounting profitability into positive operating and free cash flow. Continued cash burn, including meaningfully negative free cash flow, can require external funding and constrain investment capacity if the improvement in earnings does not persist.

History Of Losses And Weak ReturnsFluicell’s multi-year record of operating losses and negative returns on equity shows that capital has not yet generated consistently attractive results. This history weakens confidence that the latest profitability improvement represents a durable change in the business.

Profitability Durability RiskRecent positive margins have not yet been demonstrated across a long operating history, and the company’s small biotech profile makes repeatability an important risk. Failure to sustain margins as revenue scales would weaken the earnings inflection and prolong funding pressure.

FLUI FAQ

What was Fluicell AB’s price range in the past 12 months?

Fluicell AB lowest stock price was kr7.65 and its highest was kr67.20 in the past 12 months.

What is Fluicell AB’s market cap?

Fluicell AB’s market cap is kr38.33M.

When is Fluicell AB’s upcoming earnings report date?

Fluicell AB’s upcoming earnings report date is Nov 13, 2026 which is in 13 days.

How were Fluicell AB’s earnings last quarter?

Fluicell AB released its earnings results on Aug 28, 2026. The company reported kr1.645 earnings per share for the quarter.

Is Fluicell AB overvalued?

According to Wall Street analysts Fluicell AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Fluicell AB pay dividends?

Fluicell AB does not currently pay dividends.

What is Fluicell AB’s EPS estimate?

Fluicell AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Fluicell AB have?

Fluicell AB has 1,373,703 shares outstanding.

What happened to Fluicell AB’s price movement after its last earnings report?

Fluicell AB reported an EPS of kr1.645 in its last earnings report. Following the earnings report the stock price went down -11.389%.

Which hedge fund is a major shareholder of Fluicell AB?

Currently, no hedge funds are holding shares in SE:FLUI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Fluicell AB

Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.